Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Medgenics, rebranded as Aevi Genomic Medicine in 2016, was a clinical-stage biotechnology company focused on translating genetic discoveries into therapies for pediatric and adult diseases.</li>
  <li>The company's strategy centered on a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP) to identify and develop treatments for genetically defined patient populations.</li>
  <li>Following a key clinical trial failure for its lead candidate, AEVI-001, the company was acquired by Cerecor Inc. in February 2020 in an all-stock transaction valued at approximately $15.6 million, plus contingent value rights.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Medgenics, rebranded as Aevi Genomic Medicine in 2016, was a clinical-stage biotechnology company focused on translating genetic discoveries into therapies for pediatric and adult diseases.
  The company's strategy centered on a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP) to identify and develop treatments for genetically defined patient populations.
  Following a key clinical trial failure for its lead candidate, AEVI-001, the company was acquired by Cerecor Inc. in February 2020 in an all-stock transaction valued at approximately $15.6 million, plus contingent value rights.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Medgenics Inc (MDGN US) - Aug 2026

United States

Aevi Genomic Medicine, Inc. operates as a biotechnology company. The Company focuses on translating genetic discoveries into novel therapies to improve the lives of children and adults. Aevi Genomic Medicine offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Medgenics Inc (MDGN US) - Aug 2026

Medgenics, rebranded as Aevi Genomic Medicine in 2016, was a clinical-stage biotechnology company focused on translating genetic discoveries...

αSK Primers